IV. Conclusion and recommendations
The in vitro study of the 21 formulations of 7 essential drugs
available on Rwandan market has shown that most formulations meet the USP 24
requirements in term of drug content. Some among them fail to meet dissolution
requirements, others were not able to withstand storage at high temperature and
high humidity.
Based on our findings we recommend:
· A systematic evaluation of essential drug
formulations available on the Rwandan market.
· The registration of each commercially
available drug, documenting its specifications, and most importantly the
verification of these specifications.
· To perform (if possible) an in-vivo study
because the observed changes in the dissolution profiles during storage are not
necessarily indicative of impaired bioavailability.
References
Amidon G.L., Hans Lennernäs, Shah V.P. and Crison R.,
(1995) A theoretical
basis for a biopharmaceutic drug classification: the
correlation of in vitro drug product
dissolution and in vivo bioavailability. Pharm. Research
12 (3), 413-420.
Galia E., Nicolaides E., Hörter D., Löbenberg R.,
Reppas C. and Dressman J.B., (1998)
Evaluation of various dissolution media for predicting in
vivo performance of class I
and II drugs. Pharm. Research 15 (5),
698-704.
Grimm W., (1986) Stability testing in industry for worldwide
marketing.
Drug Dev. Ind. Pharm.12(8&9),
1259-1292.
Grimm W., (1992) Harmonization of guidelines on stability
testing in the E.C., Japan and USA on the move. Eur. J. Parm. Biopharm
38 (4), 154-155.
Grimm W., (1998) Extension of International Conference on
Harmonisation: tripartite
guidelines for stability testing of new drug substances and
products to countries of
zones III and IV. Drug Dev. Ind. Pharm.
24, 313-325.
Kibwage, I.O., Ogeto, J.O., Maitai, C.K., Rutere, G.,
Thuranira, J. and Ochieng, A.,
(1992) The quality work in Daru: observations during
1983-1986.
East Afr. Med. J. 69, 577-580.
Jennifer B., Dressman, Amidon G.L., Reppas C., and Shah V.P.,
(1998)
Dissolution testing as a pronostic tool for oral drug
absorption: Immediate release
dosage forms. Pharm. Research 15 (1),
11-22.
Maddock D.H. (1986) Use of generic medicines and importance of
brand names.
Pharm. J. 30, 228-278.
Matthews B.R., (1999) Regulatory aspects of stability testing
in Europe.
Drug Dev. Ind. Pharm. 25 (7), 831-856.
Murthy K.S. and Ghebre Sellasie I., (1993) Current
perspectives on the dissolution
stability of solid oral dosage forms. J. Pharm. Sci.
82(2), 113-126.
Risha P.G., Danstan S., Amani M., Masuki G., Vergote G.,
Vervaet C., and Remon
J.P., (2002) In vitro evaluation of the quality of essential
drugs on the Tanzanian
market. Trop. Med. Int. Health 7 ( 8),
701-707.
Shah, V.P., Tsong, Y. and Sathe, P., (1998) In vitro
dissolution profile comparison -
statistics and analysis of the similarity factor,
f2. Pharm. Research 15(6), 889-896.
Shakoor O., Taylor R.B. and Berhens R.H., (1997) Assesment of
the incidence of
substandard drugs in developing countries. Trop. Med. Int.
Health 2, 839-845.
Sowunmi A., Salako L.A., Ogunbona F.A. (1994) Bioavailability
of the sulfate and
dihydrchloride salts of quinine. Afr. Med. Sci.
23, 275-278.
Taylor R.B., Shakoor O., Berhens R.H., Evenard M., Low A.,
Wangbookskul J., Reid
R.G. and Kalawole J.A., (2001) Pharmacopoeial quality of
drugs supplied by Nigerian
pharmacies. Lancet 357, 1933-1936.
US Department of Health and Human Services, Center for Drug
Evaluation and
Research (CDER) (1997) Dissolution testing of immediate
release solid oral dosage
forms. Guidance for industry BP 1.
United State Pharmacopoeial Convention, (2000). United State
Pharmacopoeia
24 th edition, 12601 Twibrook
Parkway, Rockville, MD 20852.
Venho, V.M., Palva E.S., Konno K., and Stenfors E. (1987) The
value of comparative
bioavailability studies of marketed drugs in drug control:
an example with
erythromycin stearate. Fin. Exp. Clin. Pharmacol.
9, 445-447.
WHO (1997) General Policy Topic, the danger of conterfeit and
substandard active
pharmaceutical ingredients. Drug Information vol 11,
n° 3.
WHO (2000) The WHO Medicines Strategy Framework for Action in
Essential Drugs
and Medicines 2001-2003. WHO, Geneva
| 
